TherapeuticsMD, Inc.TXMD
Price (close)
$2.13
Market cap
$24.7M
P/E
—
Revenue (TTM)
$3.3M
Net income
-$217,000
Dividend yield
—
1-year total return
100.9%
Net margin
-6.6%
Revenue growth
27.8%
Debt / equity
—
What TherapeuticsMD, Inc. does.
company” refer to TherapeuticsMD, Inc., a Nevada corporation, and unless specified otherwise, include our wholly owned subsidiaries
vitaMedMD, LLC, a Delaware limited liability company (“vitaMed”), and BocaGreenMD, Inc., a Nevada corporation (“BocaGreen”).
rights to trademarks, service marks, or trade names that were previously used in connection with the operation of its business, or are
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $64.9M | $2.6M | $70.0M | $1.3M | $1.8M | $3.0M |
| Net income | -$183.5M | -$172.4M | $112.0M | -$10.3M | -$2.2M | -$569,000 |
| Free cash flow | -$159.7M | -$142.7M | — | — | — | — |
More on TXMD.
- TherapeuticsMD, Inc. summary
- TherapeuticsMD, Inc. financial statements
- TherapeuticsMD, Inc. key metrics
- TherapeuticsMD, Inc. health scores and style box
- TherapeuticsMD, Inc. earnings
- TherapeuticsMD, Inc. dividends
- TherapeuticsMD, Inc. valuation
- TherapeuticsMD, Inc. ownership and insiders
- TherapeuticsMD, Inc. peers
Figures from TherapeuticsMD, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.